ACE2‐Fc
An ACE2 fusion protein.
General information
ACE2-Fc may refer to similar but different fusion proteins serving as SARS-CoV-2 Spike protein decoys.
ACE2-Fc is a name for fusion proteins made of ACE2 residues 18 to 615 fused with human IgG1 Fc at the C-terminus and either a IL-2 secretion signalling peptide at the N-terminus (Huang et al., 2020) or an α-amylase signal peptide for Nicotiana benthamiana expression system (Castilho et al., 2021). ACE2-Fc also refers to another fusion protein expressed in Nicotiana benthamiana system. It is composed of human ACE2 receptor and IgG1 Fc with an (GGGGS)2 linker at ACE2’s C-terminus. The gene for the fusion protein was optimized for the ectopic expression (Siriwattananon et al., 2021). A version of soluble ACE2-Fc was also shown to inhibit the infection by SARS-CoV-2 Spike-pseudotyped viruses corresponding to the emergent B.1.1.7, B.1.351, and P.1 variants in vitro (Hoffmann et al., 2021). The ACE-Fc was also engineered by Ikemura et al. (2022) to reflect changes in the Omicron variant Spike. It was shown to bind Spike RBD of various Spike variants of SARS-CoV-2 and other serbecoviruses and displayed efficacy in animal viral challenges.
Synonyms
sACE2; sol-ACE2-Fc; ACE2 decoy; 3N39v4; 3J113v2; 3J320v3
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Humanized COVID‐19 decoy antibody effectively blocks viral entry and prevents SARS‐CoV‐2 infection
Spike protein ACE2 Protein factor In vitro |
Vero E6 cells; HEK293T and H1975 cells (cell phusion assay); SARS-CoV-2/NTU*/TWN/human/2020 strains (*03, 13, 14, 18, 25, or 27) | 10.28 | Blocked SARS-CoV-2 pseudotyped virus infection at the level of cell entry in vitro (cell culture and lung organoids). It also induced NK cell activation, which might improve viral clearance. |
Nov/06/2020 |
|
Generation of enzymatically competent SARS‐CoV‐2 decoy receptor ACE2‐Fc in glycoengineered Nicotiana benthamiana
Spike protein ACE2 Protein factor Enzyme assay In vitro |
in vitro binding assay; in vitro enzyme assay; Vero E6 cells; SARS-CoV-2 clinical isolate (GenBank MT093571) | 3.91 | The fusion protein was produced in a plant expression system allowing for protein glycosylation. The ACE2 domain was enzymatically competent. The fusion protein bound SARS-CoV-2 Spike RBD and neutralized the virus in vitro. |
Jan/22/2021 |
|
Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2
Spike protein ACE2 Protein factor In vitro |
in vitro binding assay; Vero E6 cells; SARS-CoV-2 | 4.40 | The plant-produced (with high yields) protein inhibited SARS-CoV-2 infection in Vero E6 cells with an IC50 of 0.84 μg/ml if added post-infection and 94.66 μg/ml if added at the pre-entry stage of infection. |
Jan/07/2021 |
|
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
Spike protein RNA Small molecule Peptide In vitro Antibody Mixed substance |
Caco-2 cells; Vero cells; Sera of vaccinated individuals; (VSV) SARS-CoV-2 Spike-pseudotyped virus (WT, B.1.1.7, B.1.351, ant P.1 variants) | 38.64 | Displayed efficacy in inhibition of Spike-pseudotyped SARS-CoV-2 in vitro. For the emergent B.1.1.7, B.1.351, and P.1 variants of Spike protein, the efficacy was slightly lower, though. |
Mar/20/2021 |
|
An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo
Spike protein ACE2 Spike variant Protein factor Animal model In vitro Antibody |
Vero E6/TMPRSS2 cells; CAG-hACE2 transgenic mice; Syrian hamsters; SARS-CoV-2 strains (Wuhan; 2019-nCoV/Japan/TY/WK-521/2020; Omicron; 2019-nCoV/Japan/TY38-873/2021); various sarbecoviral pseudotypes | 17.96 | The engineered ACE2-based decoy versions 3N39v4, 3J113v2, and 3J320v3 displayed high neutralization capacity against Omicron and other selected variants. The wild type version was capable of neutralization of various SARS-CoV-2 strains, albeit with lower efficacy for most of them compared to the engineered versions. The engineered ACE2-Fc neutralized other serbecoviruses in vitro, as well. The 3N39v4 version of ACE2-Fc was shown to provide significant protection for hamsters and humanized mice from live SARS-CoV-2 Omicron infection. Escape mutations were not observed. |
Apr/26/2022 |
